Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpha-Fluoro-carboxymethyldethia coenzyme A complex is a synthetic analog of acetyl-coenzyme A in which the sulfur atom is replaced by a methylene group and an additional fluorine atom is introduced at the alpha position. It acts as a potent inhibitor of citrate synthase, the enzyme that catalyzes the first step in the citric acid (Krebs) cycle. The compound forms stable ternary complexes with oxaloacetate and citrate synthase, mimicking transition state or intermediate structures during catalysis. Structural studies have shown that this inhibitor binds to citrate synthase with high affinity through unusually short hydrogen bonds to Asp 375 in the active site. The introduction of an alpha-fluorine increases hydrogen bond strength due to pKa matching between donor and acceptor groups[5][8]. This compound has been used primarily as a biochemical tool for mechanistic enzymology studies rather than as a therapeutic agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alpha-Fluoro-carboxymethyldethia coenzyme A complex.